Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Abstract

This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal vaccines. ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination with MenACWY for persons aged ≥2 months at increased risk for meningococcal disease caused by serogroups A, C, W, or Y, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor (e.g., eculizumab [Soliris] or ravulizumab [Ultomiris]); persons who have anatomic or functional asplenia; persons with human immunodeficiency virus infection; microbiologists routinely exposed to isolates of Neisseria meningitidis; persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroups A, C, W, or Y; persons who travel to or live in areas in which meningococcal disease is hyperendemic or epidemic; unvaccinated or incompletely vaccinated first-year college students living in residence halls; and military recruits. ACIP recommends MenACWY booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends routine use of MenB vaccine series among persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor; persons who have anatomic or functional asplenia; microbiologists who are routinely exposed to isolates of N. meningitidis; and persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroup B. ACIP recommends MenB booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends a MenB series for adolescents and young adults aged 16-23 years on the basis of shared clinical decision-making to provide short-term protection against disease caused by most strains of serogroup B N. meningitidis.

Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders

“…As meningococcal vaccination may not fully prevent meningococcemia in patients treated with complement inhibitors, the CDC recommends consideration of antibiotic prophylaxis. 98 In addition, meningococcal vaccine boosters (both quadrivalent and serogroup B) are recommended for patients with continued risk of meningococcal infections (including ongoing treatment with complement inhibitors) 99 There are no published guidelines for PJP prophylaxis in individuals with rheumatologic diseases or NMDs receiving IS agents.…”

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2021

“…Vaccine-specific changes in the 2021 child and adolescent immunization schedule for children and adolescents aged 18 years or younger include new or updated ACIP recommendations for influenza vaccine ( 4 ) meningococcal serogroups A, C, W, and Y (MenACWY) vaccines ( 5 ), and COVID-19 vaccines ( 1 , 2 ). Changes also include clarification of the recommendations for diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), Haemophilus influenzae type b vaccine (Hib), hepatitis A vaccine (HepA), hepatitis B vaccine (HepB), human papillomavirus vaccine (HPV), pneumococcal vaccines (PCV13 and PPSV23), measles, mumps, and rubella virus vaccine (MMR), tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap), and varicella vaccine (VAR).…”

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021

“…Vaccine-specific changes in the 2021 immunization schedules for adults aged ≥19 years include new or updated ACIP recommendations for influenza vaccine ( 4 ), hepatitis A vaccine (HepA) ( 5 ), hepatitis B vaccine (HepB) ( 6 ), human papillomavirus (HPV) vaccine ( 7 ), pneumococcal vaccines ( 8 ), meningococcal serogroups A, C, W, and Y (MenACWY) vaccines ( 9 ), meningococcal B (MenB) vaccines ( 9 ), and zoster vaccine ( 10 ).…”